Headlines about MEI Pharma (NASDAQ:MEIP) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MEI Pharma earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 47.7395014349525 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern’s analysis:
- Oppenheimer Holdings Brokers Increase Earnings Estimates for MEI Pharma, Inc. (MEIP) (americanbankingnews.com)
- MEI Pharma, Inc. :MEIP-US: Earnings Analysis: Q1, 2018 By the Numbers : November 9, 2017 (finance.yahoo.com)
- ETFs with exposure to MEI Pharma, Inc. : November 10, 2017 (finance.yahoo.com)
- Trading summary of Unusual Activity – MEI Pharma, Inc. (MEIP) – Wall Street Morning (wallstreetmorning.com)
Separately, Zacks Investment Research upgraded shares of MEI Pharma from a “hold” rating to a “buy” rating and set a $3.50 price objective on the stock in a report on Wednesday, July 19th.
MEI Pharma (MEIP) opened at $2.36 on Tuesday. MEI Pharma has a 1-year low of $1.34 and a 1-year high of $3.26.
MEI Pharma (NASDAQ:MEIP) last released its quarterly earnings data on Tuesday, September 5th. The company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. MEI Pharma had a negative net margin of 8.24% and a negative return on equity of 3.62%. The firm had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.60 million. analysts anticipate that MEI Pharma will post -1.05 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect MEI Pharma (MEIP) Share Price” was reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.truebluetribune.com/2017/11/14/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-mei-pharma-meip-share-price.html.
MEI Pharma Company Profile
MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Receive News & Ratings for MEI Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.